GILD
GILEAD SCIENCES, INC.
$128.10
-0.82%
$155.8B
No data for this timeframe.
Vol
Market Cap$155.8B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders11 funds
Inst. Value$36.6B
Inst. Activity2 buys / 1 sells
Insider Activity0B / 9S
Insider Net $-$6.8M
SEC Reports7
Congressional1 trades
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000882095·Prev Close $129.16
Recent Activity
Dec 23, 2026
fda_pdufa
PDUFA: GILD — anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma (4L+) — 2026-12-23
FDA target action date 2026-12-23 for GILD (GILEAD SCIENCES, INC.). Drug: anitocabtagene autoleucel
Jun 1, 2026
Insider
O'Day Daniel Patrick sold 10,900 shares
Chairman & CEO @ $131.10 ($1.4M)
May 31, 2026
SEC
14 firms acted on GILD: Jefferies, Barclays, Scotiabank, Truist Securities, Needham, Deutsche Bank, Morgan Stanley, Wolfe Research, Citigroup, Maxim Group, Leerink Partners, Bernstein, Wells Fargo, Raymond James
ANALYST-UPGRADE — Impact 2/10
May 22, 2026
Event
HEPCLUDEX
WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS D and B Severe acute exacerbations of
May 20, 2026
SEC
Maxim Group upgrades GILD to Buy — PT $165 (+26.4%)
ANALYST-UPGRADE — Impact 2/10
May 15, 2026
Insider
Mercier Johanna sold 7,749 shares
Chief Comm & Corp Aff Officer @ $130.29 ($1.0M)
May 15, 2026
Insider
Mercier Johanna sold 25,000 shares
Chief Comm & Corp Aff Officer @ $66.64 ($1.7M)
May 1, 2026
SEC
Truist Securities upgrades GILD to Buy — PT $127 (below current $130.84), while consensus mean PT $158 implies 21% upside
ANALYST-UPGRADE — Impact 2/10
Price Targets
$157.83
+25.8% upside
Strong Buy
Current $125.50
Low $122.00
Median $160.00
High $180.00
29 analysts
$122.00
$180.00
Analyst Ratings
11Strong Buy
21Buy
7Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Maxim Group | UPGRADE | Hold → Buy |
| May 8, 2026 | Truist Securities | REITERATE | Buy → Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| Apr 13, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-6.58 ▲ +4.2% | $-7.60 — $-1.31 | -427% YoY | 20 |
| Next Q | $1.78 ▼ -8.2% | $-0.89 — $2.57 | -28% YoY | 19 |
| Current FY | $-0.79 ▼ -140.9% | $-1.05 — $-0.63 | -110% YoY | 25 |
| Next FY | $9.59 ▼ -0.9% | $8.11 — $11.15 | 1306% YoY | 25 |
Latest Reports
BULLISH
ANALYST-UPGRADE
2/10
14 firms acted on GILD: Jefferies, Barclays, Scotiabank, Truist Securities, Needham, Deutsche Bank, Morgan Stanley, Wolfe Research, Citigroup, Maxim Group, Leerink Partners, Bernstein, Wells Fargo, Raymond James
May 31, 2026
MIXED
ANALYST-UPGRADE
2/10
Truist Securities upgrades GILD to Buy — PT $127 (below current $130.84), while consensus mean PT $158 implies 21% upside
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $14.9B | — |
| FMR LLC | $8.0B | ADD |
| DODGE & COX | $3.2B | — |
| MORGAN STANLEY | $2.9B | — |
| BANK OF AMERICA CORP | $2.8B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | O'Day Daniel | SELL | $1.4M |
| May 15, 2026 | Mercier Johanna | SELL | $1.0M |
| May 15, 2026 | Mercier Johanna | M | $1.7M |
| May 15, 2026 | Dickinson Andrew | SELL | $396.8K |
| May 15, 2026 | Mercier Johanna | M | $0.00 |
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Joshua Gottheimer | D | BUY | $1,001 - $15,000 |
11 institutional holders with $36.6B total value (298,593,768 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, DODGE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 121,097,336 | $14.9B | 40.6% | — |
| 2 | FMR LLC | 65,579,490 | $8.0B | 22.0% | ADD +45.2% |
| 3 | DODGE & COX | 26,283,511 | $3.2B | 8.8% | — |
| 4 | MORGAN STANLEY | 23,512,734 | $2.9B | 7.9% | — |
| 5 | BANK OF AMERICA CORP /DE/ | 23,121,620 | $2.8B | 7.7% | — |
| 6 | NORGES BANK | 21,322,732 | $2.6B | 7.1% | NEW |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 8,006,790 | $982.8M | 2.7% | NEW |
| 8 | WELLS FARGO & COMPANY/MN | 6,664,675 | $818.0M | 2.2% | — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 2,788,728 | $342.3M | 0.9% | TRIM -49.0% |
| 10 | ARIEL INVESTMENTS, LLC | 205,052 | $25.2M | 0.1% | TRIM -40.7% |
| 11 | TWO SIGMA INVESTMENTS, LP | 11,100 | $1.4M | 0.0% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 21,322,732 | — | $2.6B | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 5,462,744 | 2,788,728 | -49.0% | $342.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 11,100 | — | $1.4M | 2025-Q4 |
| ARIEL INVESTMENTS, LLC | TRIM | 368,861 | 218,778 | -40.7% | $24.3M | 2025-Q3 |
| NORGES BANK | EXIT | 19,394,502 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 19,394,502 | — | $2.2B | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 43,400 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | ADD | 40,319,432 | 58,542,842 | +45.2% | $6.6B | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 239,962 | 43,400 | -81.9% | $4.9M | 2025-Q1 |
| NORGES BANK | EXIT | 19,370,510 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 4,188,524 | 5,329,743 | +27.2% | $492.3M | 2024-Q4 |
| ARIEL INVESTMENTS, LLC | ADD | 237,048 | 399,794 | +68.7% | $36.9M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 7,752,975 | — | $650.0M | 2024-Q3 |
14 unique insiders with 9 transactions. Net insider value: -$6.8M ($0.00 bought, $6.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | 10,900 | $131.10 | $1.4M |
| May 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 7,749 | $130.29 | $1.0M |
| May 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | M | 25,000 | $66.64 | $1.7M |
| May 15, 2026 | Dickinson Andrew D | Chief Financial Officer | SELL | 3,000 | $132.27 | $396.8K |
| May 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | M | 25,000 | $0.00 | $0.00 |
| Apr 30, 2026 | Kramer Kelly A. | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 30, 2026 | Kramer Kelly A. | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | MANWANI HARISH | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | MANWANI HARISH | Director | F | 224 | $130.84 | $29.3K |
| Apr 30, 2026 | MANWANI HARISH | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 30, 2026 | WELTERS ANTHONY | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | WELTERS ANTHONY | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 30, 2026 | LOVE TED W | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | LOVE TED W | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 30, 2026 | Rodriguez Javier | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 30, 2026 | Rodriguez Javier | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | Horning Sandra | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | Horning Sandra | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 30, 2026 | BARTON JACQUELINE K | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | BARTON JACQUELINE K | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 30, 2026 | Bluestone Jeffrey | Director | A | 1,146 | $0.00 | $0.00 |
| Apr 30, 2026 | Bluestone Jeffrey | Director | A | 4,884 | $0.00 | $0.00 |
| Apr 28, 2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | 6,950 | $128.79 | $895.1K |
| Apr 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 3,000 | $140.96 | $422.9K |
| Apr 15, 2026 | Dickinson Andrew D | Chief Financial Officer | SELL | 3,000 | $140.96 | $422.9K |
| Mar 27, 2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | 10,000 | $136.82 | $1.4M |
| Mar 16, 2026 | Dickinson Andrew D | Chief Financial Officer | SELL | 3,000 | $144.23 | $432.7K |
| Mar 16, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 3,000 | $144.23 | $432.7K |
| Mar 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | M | 20,026 | $0.00 | $0.00 |
| Mar 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | A | 32,815 | $0.00 | $0.00 |
| Mar 10, 2026 | Berger Dietmar | Chief Medical Officer | M | 2,133 | $0.00 | $0.00 |
| Mar 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | A | 122,755 | $0.00 | $0.00 |
| Mar 10, 2026 | Berger Dietmar | Chief Medical Officer | M | 2,133 | $0.00 | $0.00 |
| Mar 10, 2026 | Berger Dietmar | Chief Medical Officer | A | 8,415 | $0.00 | $0.00 |
| Mar 10, 2026 | Berger Dietmar | Chief Medical Officer | A | 31,475 | $0.00 | $0.00 |
| Mar 10, 2026 | Berger Dietmar | Chief Medical Officer | F | 1,063 | $148.56 | $157.9K |
| Mar 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | F | 9,767 | $148.56 | $1.5M |
| Mar 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | M | 20,026 | $0.00 | $0.00 |
| Mar 10, 2026 | Burkhart Erin | SVP, Controllership | A | 2,355 | $0.00 | $0.00 |
| Mar 10, 2026 | Burkhart Erin | SVP, Controllership | A | 5,455 | $0.00 | $0.00 |
| Mar 10, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | F | 3,216 | $148.56 | $477.8K |
| Mar 10, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | M | 6,617 | $0.00 | $0.00 |
| Mar 10, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | A | 35,880 | $0.00 | $0.00 |
| Mar 10, 2026 | Dickinson Andrew D | Chief Financial Officer | F | 3,147 | $148.56 | $467.5K |
| Mar 10, 2026 | Dickinson Andrew D | Chief Financial Officer | M | 6,469 | $0.00 | $0.00 |
| Mar 10, 2026 | Dickinson Andrew D | Chief Financial Officer | M | 6,469 | $0.00 | $0.00 |
| Mar 10, 2026 | Dickinson Andrew D | Chief Financial Officer | A | 35,880 | $0.00 | $0.00 |
| Mar 10, 2026 | Dickinson Andrew D | Chief Financial Officer | A | 9,590 | $0.00 | $0.00 |
| Mar 10, 2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | F | 606 | $148.56 | $90.0K |
| Mar 10, 2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | M | 1,246 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 3 neutral. Avg impact: 3.3/10.
BULLISH
ANALYST-UPGRADE
2/10
14 firms acted on GILD: Jefferies, Barclays, Scotiabank, Truist Securities, Needham, Deutsche Bank, Morgan Stanley, Wolfe Research, Citigroup, Maxim Group, Leerink Partners, Bernstein, Wells Fargo, Raymond James
May 31, 2026
MIXED
ANALYST-UPGRADE
2/10
Truist Securities upgrades GILD to Buy — PT $127 (below current $130.84), while consensus mean PT $158 implies 21% upside
May 1, 2026
BULLISH
ANALYST-UPGRADE
2/10
Maxim Group upgrades GILD to Buy — PT $165 (+26.4%)
May 20, 2026
NEUTRAL
424B5
4/10
Gilead Sciences is issuing $3.0 billion in senior unsecured notes across four tranches (2028-2034),
May 18, 2026
NEUTRAL
424B5
4/10
Gilead Sciences filed a preliminary 424B5 prospectus supplement for a multi-tranche senior unsecured
May 14, 2026
BEARISH
CLUSTER
6/10
Two Gilead Sciences executives — the CFO and Chief Communications Officer — each sold 3,000 shares i
Apr 16, 2026
NEUTRAL
DEFA14A
3/10
Gilead Sciences is holding its 2026 Annual Meeting, where shareholders will vote on several key prop
Mar 20, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 39 analysts: 11 strong buy, 21 buy, 7 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$157.83 mean target
+25.8% upside
Strong Buy (1.65)
$122.00 Low
$180.00 High
| Metric | Value |
|---|---|
| Current Price | $125.50 |
| Target Low | $122.00 |
| Target Mean | $157.83 |
| Target Median | $160.00 |
| Target High | $180.00 |
| # Analysts | 29 |
| Recommendation | Strong Buy (1.65) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-6.58 | $-7.60 | $-1.31 | -427.2% | +4.2% | 0↑ 15↓ | $7.4B | 4.6% | 20 |
| Next Q 2026-09-30 |
$1.78 | $-0.89 | $2.57 | -28.1% | -8.2% | 5↑ 10↓ | $7.8B | 0.2% | 19 |
| Current FY 2026-12-31 |
$-0.79 | $-1.05 | $-0.63 | -109.7% | -140.9% | 0↑ 22↓ | $30.5B | 3.4% | 25 |
| Next FY 2027-12-31 |
$9.59 | $8.11 | $11.15 | 1305.8% | -0.9% | 9↑ 13↓ | $32.4B | 6.2% | 25 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-6.576 | |
| 7d ago | $-6.576 | |
| 30d ago | $-6.862 | +0.286 |
| 60d ago | $1.917 | -8.493 |
| 90d ago | $2.099 | -8.675 |
12 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Maxim Group | UPGRADE | Hold | Buy |
| May 8, 2026 | Truist Securities | REITERATE | Buy | Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Apr 13, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 10, 2026 | Jefferies | INITIATE | — | Buy |
| Feb 23, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 20, 2026 | Barclays | INITIATE | — | Equal-Weight |
| Feb 11, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Feb 11, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 11, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 11, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 11, 2026 | Scotiabank | MAINTAIN | Sector Outperform | Sector Outperform |
| Feb 11, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Jan 7, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 11 | 21 | 7 | 0 | 0 | 82% | |
| May 1, 2026 | 11 | 20 | 8 | 0 | 0 | 79% | |
| Apr 1, 2026 | 11 | 20 | 8 | 0 | 0 | 79% | |
| Mar 1, 2026 | 10 | 20 | 8 | 0 | 0 | 79% | |
| Feb 1, 2026 | 10 | 20 | 7 | 0 | 0 | 81% | |
| Jan 1, 2026 | 10 | 19 | 8 | 0 | 0 | 78% | |
| Dec 1, 2025 | 10 | 19 | 8 | 0 | 0 | 78% | |
| Nov 1, 2025 | 10 | 18 | 8 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Joshua Gottheimer | D | HOUSE | BUY | $1,001 - $15,000 | Gilead Sciences Inc | Feb 27, 2026 (32d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Dec 23, 2026
fda_pdufa
PDUFA: GILD — anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma (4L+) — 2026-12-23
FDA target action date 2026-12-23 for GILD (GILEAD SCIENCES, INC.). Drug: anitocabtagene autoleucel (anito-cel). Indication: relapsed or refractory mu
Aug 27, 2026
fda_pdufa
PDUFA: GILD — bictegravir and lenacapavir (BIC LEN) in virologically suppressed HIV — 2026-08-27
FDA target action date 2026-08-27 for GILD (GILEAD SCIENCES, INC.). Drug: bictegravir and lenacapavir (BIC LEN). Indication: virologically suppressed
Aug 5, 2026
earnings_calendar
GILD Q2 2026 Earnings After Market Close — 2026-08-05
EPS est: $2.13 | Rev est: $7.6B
Jun 9, 2026
Clinical Trial
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
Phase Phase 2 — TERMINATED
Jun 9, 2026
Clinical Trial
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Phase Phase 2 — COMPLETED
Jun 9, 2026
clinical_trial_readout
Results Pending: Brexucabtagene Autoleucel (KTE-X19) (Phase 2) — Completed 76d ago
Trial: Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lympho
Jun 4, 2026
Clinical Trial
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Phase Phase 3 — COMPLETED
Jun 4, 2026
clinical_trial_readout
Results Pending: Seladelpar 10 mg (Phase 3) — Completed 29d ago
Trial: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (P
Jun 3, 2026
Clinical Trial
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
Clinical Trial
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Sacituzumab Govitecan-hziy (SG) (Phase 2)
Trial: Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSC
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Filgotinib (Phase 3)
Trial: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Sponsor: Alfasigma S.p.A.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUIT
May 26, 2026
short_volume
Short Volume: GILD — 56.8% short (1.3M / 2.2M)
Short: 1,268,855 | Exempt: 2,247 | TRF Vol: 2,233,829 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 22, 2026
FDA
HEPCLUDEX
WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS D and B Severe acute exacerbations of hepatitis D and hepatitis B may occur after HEPCLU
May 22, 2026
FDA
HEPCLUDEX
Original Approval — Type 1 - New Molecular Entity — BULEVIRTIDE — INJECTION — SUBCUTANEOUS
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Domvanalimab (Phase 2)
Trial: Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
May 18, 2026
dark_pool
Dark Pool: GILD — 7.1M shares, 115,100 trades
Week starting 2026-05-18. Total ATS volume: 7,095,050 shares across 115,100 trades.
May 12, 2026
short_interest
FTD: GILD — 7,252 shares ($1.0M) failed to deliver
Settlement: 20260512, Price: $133.52, FTD Value: $968,287.04, GILEAD SCIENCES INC
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Domvanalimab (Phase 2)
Trial: Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
May 11, 2026
short_interest
FTD: GILD — 21,146 shares ($2.8M) failed to deliver
Settlement: 20260511, Price: $131.33, FTD Value: $2,777,104.18, GILEAD SCIENCES INC
May 11, 2026
dark_pool
Dark Pool: GILD — 7.0M shares, 127,430 trades
Week starting 2026-05-11. Total ATS volume: 6,952,760 shares across 127,430 trades.
May 9, 2026
clinical_trial_readout
Results Pending: Brexucabtagene Autoleucel (KTE-X19) (Phase 2) — Completed 45d ago
Trial: Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lympho
Feb 17, 2026
FDA
IDELALISIB
Feb 17, 2026
FDA
IDELALISIB
Dec 22, 2022
FDA
SUNLENCA